- Capital Cube•6 months ago
Grifols SA relative valuation is now NEUTRAL. It was previously rated OVERVALUED, and has a fundamental analysis score of 47.Our analysis is based on comparing Grifols SA with the following peers – Baxter International Inc., Amgen Inc., China Cord Blood Corporation, Kimberly-Clark Corporation, Johnson & Johnson, Cord Blood America, Inc. and GlaxoSmithKline plc Sponsored ADR […] (Read more...) The post Grifols SA : Fairly valued, but don’t skip the other factors appeared first on CapitalCube.
- Moody's•10 months ago
London, 13 October 2015-- Moody's Investors Service has today affirmed the Ba2 corporate family rating and the Ba2-PD probability of default rating of Grifols S.A., a global healthcare company primarily ...
|Day's Range||0.00 - 0.00|
|Avg Vol (3m)||80|
As of 3:21 PM EDT. Market closed.